← Back to Search

Chemotherapy

Treatment for Esophageal Cancer

N/A
Waitlist Available
Led By David Cunningham
Research Sponsored by Royal Marsden NHS Foundation Trust
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Any patient with histologically proven operable ,locally advanced and metastatic oesophageal or gastric carcinoma.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

Knowledge of the impact of gene expression profiling could allow optimisation of chemotherapy regimens for individual patients. It could ensure that patients do not receive a particular form of chemotherapy if it is unlikely to benefit them, and in these circumstances an alternative form of chemotherapy that may prove beneficial could be selected. This information will therefore allow chemotherapy to be tailored to the individual tumour. It may help identify those patients with a poorer prognosis who could be selected for further therapy post surgery or a different treatment strategy at the outset.

Eligible Conditions
  • Esophageal Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Find a Location

Who is running the clinical trial?

Royal Marsden NHS Foundation TrustLead Sponsor
323 Previous Clinical Trials
10,150,387 Total Patients Enrolled
David CunninghamPrincipal InvestigatorRoyal Marsden NHS Foundation Trust
15 Previous Clinical Trials
2,038 Total Patients Enrolled
~17 spots leftby Oct 2025